Penumbra Earnings Preview: BSX Takeover Makes This Print a Deal Test

Penumbra reports Q3 results on November 2 against a backdrop that has shifted fundamentally since its last print. A agreed acquisition by Boston Scientific means the earnings call is now as much about deal confidence as underlying business momentum.

The most telling signal heading into the print is not short interest or options skew but the BSX stock itself. BSX fell 5.8% on October 29, dragging the acquisition spread wider on the day PEN's put/call ratio climbed to its highest level of the past year, 3.07, almost two standard deviations above its 20-day average of 2.46. That combination points to heavier demand for downside protection than at any point in the past 12 months. PEN itself has been range-bound, up roughly 1.1% on the day but down slightly on the week to $321.97, well below the $362 consensus analyst target. The borrow market tells a calmer story: availability is ample at 905%, and cost to borrow is a modest 1.68%, with no squeeze pressure evident in the lending pool.

Short interest has climbed, but from a low base. It has risen 56% over the past month to 5.8% of the free float, the bulk of that move coming in a single step around October 9. Days to cover stand at 6.76 according to the latest FINRA settlement data. That is enough to watch but not enough to call PEN a heavily shorted name. The ORTEX short score of 50 sits at the midpoint of its range, consistent with a stock where the short case is emerging rather than entrenched.

The analyst community is effectively neutral, with 14 hold ratings and a consensus price target of $362. Most of the recent analyst activity predates the acquisition news; the last major moves were downgrades from Jefferies, Canaccord and Citigroup in January 2026 as the stock approached valuation ceilings. Evercore ISI, which carries the lone Outperform among recent changes, cut its target twice in 2026, first to $335 in May then to $320 in July, pricing the stock almost exactly where it trades today. The bull case rests on Penumbra's leadership in thrombectomy and embolization markets, mid-teens revenue growth and the strategic value of those franchises to an acquirer. Bears point to reimbursement pressure, competition in mechanical thrombectomy and execution risk on margins, arguments that matter less if the deal closes cleanly but more if it does not.

ORTEX Index Rebalance Radar puts the probability of PEN being deleted from the S&P MidCap 400 at 80%, with an estimated $1.8 billion of index tracker selling to execute around December 14. Deletion from the MSCI World Small index carries an 65% probability and a further estimated $867 million in selling. These are forecasts, not announcements, and all dates are estimated. In 39 past S&P MidCap deletions from similar acquisition events, the median move from announcement to effective date was minus 1%, with trade-day volume running at 11.5 times the normal level.

The November 2 print will therefore test something narrower than a typical earnings release: whether Penumbra's underlying revenue trajectory and margin profile give deal-watchers a reason to stay patient, or whether any operational disappointment widens the acquisition discount further.